Hydrogels for oral delivery of therapeutic proteins.
In recent years there has been significant new interest in the development of transmucosal (mostly oral) pharmaceutical formulations for the delivery of therapeutic proteins. Emphasis has been given to the molecular design of new carriers for the delivery of insulin, calcitonin and various types of interferons for the treatment of diabetes, osteoporosis, multiple sclerosis and cancer. Most popular carriers include advanced designs of swollen hydrogels prepared from neutral or intelligent polymeric networks. In this review, the most successful of such systems are presented and their promise in the field described.
Peppas
Nicholas A
NA
University of Texas at Austin, Laboratory for Biomaterials, Drug Delivery, Bionanotechnology and Molecular Recognition, Department of Chemical Engineering, Austin, TX 78712, USA.
Wood
Kristy M
KM
Blanchette
James O
JO
D000284:Administration, Oral; D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage; D001786:Blood Glucose / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage; D003920:Diabetes Mellitus / Q000628:therapy; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D007328:Insulin / Q000008:administration & dosage; D007372:Interferons / Q000008:administration & dosage; D008954:Models, Biological; D009103:Multiple Sclerosis / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D010024:Osteoporosis / Q000628:therapy; D013997:Time Factors
D001672:Biocompatible Materials; D001786:Blood Glucose; D007328:Insulin; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D002116:Calcitonin; D007372:Interferons